

2. Provide a benzene job-exposure matrix for cases and controls used in the case-control study. The matrix will consider job, task, industry and time period in developing exposure estimates to benzene. Data sources for exposure assessment including the IPHS data set, Yang Pu database, the Chinese literature, real-time monitoring in selected factories and simulations will be used to arrive at credible benzene exposure estimates.
3. Provide a test data set consisting of all diagnosed and verified AMLs and lymphoid neoplasms (WHO 2001) and their matched controls, including detailed subtype diagnostic classifications, confounders and job-exposure matrix, and all questionnaire information (such as medical histories, family histories, lifestyle information, etc.) for testing the case-control protocol and for developing analytical programs to Applied Health Sciences by mid-September 2007*. [RDW – Talk to Rob Schnatter/Otto Wong]
4. Provide a final data set consisting of all diagnosed and verified AMLs and lymphoid neoplasms (WHO 2001) and their matched controls, including detailed subtype diagnostic classifications, confounders and job-exposure matrix, and all questionnaire information (such as medical histories, family histories, lifestyle information, etc.) for completion of the case-control protocol to Applied Health Sciences by July 1, 2008*.
5. Provide an account of all eligible AML and lymphoid neoplasm patients at all participating hospitals, who did not agree to participate or who were not interviewed, including their basic demographic information and reasons for non-participation/non-interview (if available).

*Based on a timeline agreed upon in cooperation with the independent QA/QC team.

Disease Progression Studies

1. Provide publication quality manuscript(s) presenting the findings of the Disease Progression protocol following the guidelines in Cinpathogen's March 18, 2007 DPME proposal, Section 3.1-A by November 1, 2008

Molecular Epidemiology Study

1. Provide publication quality manuscript(s) presenting the findings of the Molecular Epidemiology protocol following the guidelines in Cinpathogen's March 18, 2007 DPME proposal, Section 3.1-A by November 1, 2008.

Project Management

1. Implementation of the conditions one and three in the agreement for advance funding for Cinpathogen (Red Cavaney to Richard Irons, April 11, 2007).
2. Implementation of recommendations from the independent QA/QC team.
3. Provide semi-annual progress report to the Scientific and Ethics Review Panelists, Shanghai Health Study sponsors, and API. The update should include a cumulative